Gilead Sciences (GILD) Q1 FY2026 earnings: revenue $7.0 billion, up 4.4% on the year
Gilead Sciences, Inc. (GILD) reported revenue of $7.0 billion for Q1 FY2026, the quarter ended 31 March 2026, up 4.4% on the same quarter a year earlier. Net income was $2.0 billion, up 53.7% on the year, and diluted earnings per share $1.61. The figures are the company's own, from the 10-Q it filed with the SEC on 7 May 2026.
Revenue
$7.0 billion
+4.4% on the year · -12.2% on the quarter
Q2 FY2024Q1 FY2026
Operating margin
37.2%
33.6% a year earlier
Q2 FY2024Q1 FY2026
Net income
$2.0 billion
+53.7% on the year · -7.4% on the quarter
Q2 FY2024Q1 FY2026
Diluted EPS
$1.61
+54.8% on the year · -7.5% on the quarter
Q2 FY2024Q1 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
Revenue up 4% to $7.0 billion: Total revenues were $7.0 billion, up 4%, with higher HIV, Trodelvy and Livdelzi sales, partly offset by lower Veklury, HCV and Cell Therapy sales.
Product sales ex-Veklury up 8%: Product sales excluding Veklury were $6.8 billion, up 8%, led by HIV, Trodelvy and Livdelzi, partly offset by lower HCV and Cell Therapy sales.
Non-GAAP EPS up 12%: Non-GAAP diluted EPS was $2.03 against $1.81, driven by higher product sales and lower acquired IPR&D expenses, partly offset by higher income tax and SG&A.
$ million except per share. Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q1 FY2026
Q4 FY2025
Q1 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
2,544
3,327
1,757
-23.5%
+44.8%
Capital expenditure
117
205
104
-42.9%
+12.5%
Free cash flow
2,427
3,122
1,653
-22.3%
+46.8%
Free cash flow margin
34.9%
39.4%
24.8%
Cash from investing
1,770
-1,835
-415
Cash from financing
-4,239
-1,263
-3,426
Share-based compensation
218
230
209
-5.2%
+4.3%
Buybacks
419
230
730
+82.2%
-42.6%
Dividends paid
1,040
994
1,010
+4.6%
+3.0%
Dividend per share
$0.82
n/a
$0.79
+3.8%
Diluted shares, weighted
1,254m
1,253m
1,259m
+0.1%
-0.4%
Shares outstanding at period end
1,242m
1,241m
1,245m
+0.1%
-0.2%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q1 FY2026
Q4 FY2025
Q1 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
23,515
22,703
19,162
+3.6%
+22.7%
Non-controlling interest
-84.0
-84.0
-84.0
Debt
22,174
24,937
24,952
-11.1%
-11.1%
Operating lease liabilities
n/a
503
n/a
Other liabilities
10,673
10,964
12,404
-2.7%
-14.0%
Total liabilities and equity
56,278
59,023
56,434
-4.7%
-0.3%
Fixed assets
5,638
5,606
5,421
+0.6%
+4.0%
Goodwill
8,314
8,314
8,314
0.0%
0.0%
Intangible assets
16,382
16,978
19,355
-3.5%
-15.4%
Investments
998
3,042
n/a
-67.2%
Cash and equivalents
7,628
7,564
7,926
+0.8%
-3.8%
Receivables
4,741
4,913
4,388
-3.5%
+8.0%
Inventory
1,914
1,774
1,759
+7.9%
+8.8%
Other assets
10,663
10,832
9,271
-1.6%
+15.0%
Total assets
56,278
59,023
56,434
-4.7%
-0.3%
Questions
What was Gilead Sciences' revenue in Q1 FY2026?
Gilead Sciences (GILD) reported revenue of $7.0 billion for Q1 FY2026, the quarter ended 31 March 2026, up 4.4% on the same quarter a year earlier.
How much did Gilead Sciences earn in Q1 FY2026?
Net income for Q1 FY2026 was $2.0 billion, up 53.7% on the year, and diluted earnings per share $1.61.
When did Gilead Sciences report Q1 FY2026 results?
Gilead Sciences filed its 10-Q for the quarter ended 31 March 2026 with the SEC on 7 May 2026.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 31 March 2026, filed 7 May 2026: the filing.